|
CA1305177C
(en)
|
1987-06-30 |
1992-07-14 |
Yasufumi Ohfune |
Carboxycyclopropylglycine and process for producing the same
|
|
US4904681A
(en)
|
1987-12-01 |
1990-02-27 |
G. D. Searle & Co. |
D-cycloserine and its prodrugs as cognitive enhancers
|
|
EP0360390A1
(en)
|
1988-07-25 |
1990-03-28 |
Glaxo Group Limited |
Spirolactam derivatives
|
|
US5061721A
(en)
|
1989-03-15 |
1991-10-29 |
G. D. Searle & Co. |
Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
|
|
US5086072A
(en)
|
1990-06-18 |
1992-02-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
|
|
WO1992007561A1
(en)
|
1990-10-30 |
1992-05-14 |
Ss Pharmaceutical Co., Ltd. |
Antiphlogistic and analgesic gel preparation
|
|
US5168103A
(en)
|
1991-01-22 |
1992-12-01 |
American Home Products Corporation |
[[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
|
|
FR2692268B1
(fr)
|
1992-06-15 |
1994-08-19 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations.
|
|
SE9301667D0
(sv)
|
1993-05-14 |
1993-05-14 |
Kabi Pharmacia Ab |
New use
|
|
US5523323A
(en)
|
1993-09-14 |
1996-06-04 |
Maccecchini; Maria-Luisa |
Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
|
|
US5605911A
(en)
|
1995-01-31 |
1997-02-25 |
Washington University |
Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
|
|
US6335358B1
(en)
|
1995-04-12 |
2002-01-01 |
President And Fellows Of Harvard College |
Lactacystin analogs
|
|
US5741778A
(en)
|
1996-03-19 |
1998-04-21 |
Amgen Inc. |
Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
|
|
US5763393A
(en)
|
1996-05-17 |
1998-06-09 |
Neurotherapeutics L.P. |
Neuroactive peptides
|
|
CA2252417A1
(en)
|
1996-06-07 |
1997-12-11 |
Zeneca Limited |
Peptide derivatives
|
|
EP0918859A1
(en)
|
1996-08-02 |
1999-06-02 |
ZymoGenetics, Inc. |
Testis-specific insulin homolog polypeptides
|
|
US5902815A
(en)
|
1996-09-03 |
1999-05-11 |
Washington University |
Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
|
|
JP3955345B2
(ja)
|
1996-09-27 |
2007-08-08 |
サントリー株式会社 |
新規アミノ酸ダイジハーベイン
|
|
WO1999024584A1
(en)
|
1997-11-12 |
1999-05-20 |
Neurotherapeutics |
Methods for the detection and treatment of disease using a glycosyltransferase
|
|
US5952389A
(en)
|
1998-01-13 |
1999-09-14 |
Synchroneuron |
Methods of treating tardive dyskinesia and other movement disorders
|
|
US6007841A
(en)
|
1998-03-13 |
1999-12-28 |
Algos Pharmaceutical Corporation |
Analgesic composition and method for treating pain
|
|
US6274314B1
(en)
|
1998-04-02 |
2001-08-14 |
Nyxis Neurotherapies, Inc. |
Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine
|
|
US6197820B1
(en)
|
1998-04-06 |
2001-03-06 |
Uab Research Foundation |
Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions
|
|
US6025471A
(en)
|
1998-06-03 |
2000-02-15 |
Deghenghi; Romano |
Diazaspiro, azepino and azabicyclo therapeutic peptides
|
|
AU1724000A
(en)
|
1998-11-12 |
2000-05-29 |
Nyxis, Inc. |
Diagnostic assay for cancer
|
|
US20030064921A1
(en)
|
1999-10-27 |
2003-04-03 |
The Regents Of The University Of California |
Methods and compounds for modulating melanocortin receptor ligand binding and activity
|
|
AU1922301A
(en)
|
1999-11-17 |
2001-05-30 |
Nyxis Neurotherapies, Inc. |
Differential gene expression in cancer
|
|
AU782678B2
(en)
|
2000-02-01 |
2005-08-18 |
Agy Therapeutics, Inc. |
Interaction of NMDA receptor with protein tyrosine phosphatase
|
|
AU2001268467A1
(en)
|
2000-06-14 |
2001-12-24 |
Nyxis Neurotherapies, Inc. |
Identification of genes and compounds for treatment of cancer
|
|
WO2001098367A2
(en)
|
2000-06-22 |
2001-12-27 |
Nyxis Neurotherapies, Inc. |
Neuroactive peptides for treatment of hypoxia and related conditions
|
|
GB0018272D0
(en)
|
2000-07-25 |
2000-09-13 |
Vernalis Research Limited |
Chemical compounds IV
|
|
IL145209A0
(en)
|
2000-09-06 |
2002-06-30 |
Pfizer Prod Inc |
Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
|
|
EP1186303A3
(en)
|
2000-09-06 |
2003-12-10 |
Pfizer Products Inc. |
Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
|
|
UA73619C2
(en)
|
2000-12-13 |
2005-08-15 |
Pfizer Prod Inc |
Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
|
|
US20020142287A1
(en)
|
2000-12-14 |
2002-10-03 |
Hirotaka Yamamoto |
High throughput assay to detect inhibitors of the map kinase pathway
|
|
WO2002072005A2
(en)
|
2001-03-07 |
2002-09-19 |
University Of Utah Research Foundation |
Linear y-carboxyglutamate rich conotoxins
|
|
WO2002072609A2
(en)
|
2001-03-12 |
2002-09-19 |
Nyxis Neurotherapies, Inc |
Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain
|
|
WO2003010540A1
(en)
|
2001-07-25 |
2003-02-06 |
Nyxis Neurotherapies, Inc. |
Method of identifying nmda-related agent
|
|
ES2355157T3
(es)
|
2002-07-05 |
2011-03-23 |
Targacept, Inc. |
Compuestos diazaspirocíclico n-arilo y métodos de preparación y uso de las mismas.
|
|
US7273889B2
(en)
|
2002-09-25 |
2007-09-25 |
Innovative Drug Delivery Systems, Inc. |
NMDA receptor antagonist formulation with reduced neurotoxicity
|
|
CA2534909A1
(en)
|
2003-08-08 |
2005-02-17 |
The Burnham Institute |
P16 mediated regulation of nmda receptors
|
|
WO2005020973A2
(en)
|
2003-08-29 |
2005-03-10 |
The University Of Houston System |
Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxylamine
|
|
GB0323204D0
(en)
|
2003-10-03 |
2003-11-05 |
Novartis Ag |
Organic compounds
|
|
US20050096311A1
(en)
|
2003-10-30 |
2005-05-05 |
Cns Response |
Compositions and methods for treatment of nervous system disorders
|
|
US20060063707A1
(en)
|
2004-09-17 |
2006-03-23 |
Lifelike Biomatic, Inc. |
Compositions for enhancing memory and methods therefor
|
|
EP2030622B1
(en)
|
2005-03-24 |
2011-02-23 |
Emory University |
Indication of dosage of progesterone in the treatment of a traumatic brain injury
|
|
US7631994B2
(en)
|
2005-07-11 |
2009-12-15 |
Lights Of America, Inc. |
Mounting system for a light fixture
|
|
EP1945691A2
(en)
|
2005-08-26 |
2008-07-23 |
Wisconsin Alumni Research Foundation |
Poly-beta-peptides from functionalized beta-lactam monomers and antibacterial compositions containing same
|
|
AR059224A1
(es)
|
2006-01-31 |
2008-03-19 |
Jerini Ag |
Compuestos para la inhibicion de integrinas y uso de estas
|
|
US20070208001A1
(en)
|
2006-03-03 |
2007-09-06 |
Jincong Zhuo |
Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
|
|
CA2663502A1
(en)
|
2006-09-15 |
2008-03-20 |
Schering Corporation |
Azetidinone derivatives and methods of use thereof
|
|
JP2008188285A
(ja)
|
2007-02-06 |
2008-08-21 |
Bridgestone Corp |
バックパッド及び車両用シート
|
|
CN101066945B
(zh)
|
2007-05-25 |
2010-05-19 |
中国科学院上海有机化学研究所 |
一种合成3-位取代内酰胺类化合物的方法
|
|
CN101125817B
(zh)
|
2007-08-03 |
2011-09-14 |
中国科学院上海有机化学研究所 |
一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法
|
|
WO2009039390A2
(en)
|
2007-09-20 |
2009-03-26 |
Naurex Inc. |
The development of glycobiology-based therapeutics for the treatment of brain tumors
|
|
AU2009217278B2
(en)
|
2008-02-20 |
2015-08-20 |
The Children's Hospital Of Philadelphia |
Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism
|
|
CA2732091A1
(en)
|
2008-08-07 |
2010-02-11 |
F. Hoffmann-La Roche Ag |
Process for the preparation of a macrocycle
|
|
JP5702288B2
(ja)
|
2008-09-18 |
2015-04-15 |
ノースウエスタン ユニバーシティ |
Ｎｍｄａレセプターモジュレータ及びその用途
|
|
WO2010065709A2
(en)
|
2008-12-03 |
2010-06-10 |
Amin Khan |
Hydroxamic acid derivatives, preparation and therapeutic uses thereof
|
|
DE102009001460B4
(de)
|
2009-03-11 |
2010-12-02 |
Zf Friedrichshafen Ag |
Ölbehälter
|
|
WO2011003064A2
(en)
|
2009-07-02 |
2011-01-06 |
Naurex, Inc. |
Methods of treating neuropathic pain
|
|
US8951968B2
(en)
|
2009-10-05 |
2015-02-10 |
Northwestern University |
Methods of treating depression and other related diseases
|
|
EP3488856A1
(en)
|
2009-10-05 |
2019-05-29 |
Northwestern University |
Methods of treating depression and other related diseases
|
|
SG183265A1
(en)
|
2010-02-11 |
2012-09-27 |
Univ Northwestern |
Secondary structure stabilized nmda receptor modulators and uses thereof
|
|
KR101692275B1
(ko)
|
2010-02-11 |
2017-01-04 |
노오쓰웨스턴 유니버시티 |
２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
|
|
US9737531B2
(en)
|
2012-07-12 |
2017-08-22 |
Glytech, Llc |
Composition and method for treatment of depression and psychosis in humans
|
|
EP2701721A4
(en)
|
2011-04-27 |
2015-12-16 |
Univ Northwestern |
METHOD FOR THE TREATMENT OF MORBUS ALZHEIMER, MORBUS HUNTINGTON, AUTISM OR OTHER DISORDERS
|
|
US9293690B2
(en)
|
2011-06-27 |
2016-03-22 |
Koninklijke Philips N.V. |
Ultrasound transducer assembly and method of manufacturing the same
|
|
ES2791308T3
(es)
|
2011-07-27 |
2020-11-03 |
Astrazeneca Ab |
Derivados de 2-(2,4,5-anilino sustituido)pirimidina como moduladores de EGFR útiles para tratar el cáncer
|
|
CA2899191A1
(en)
|
2013-01-29 |
2014-08-07 |
Naurex, Inc. |
Spiro-lactam nmda receptor modulators and uses thereof
|
|
KR20150110586A
(ko)
|
2013-01-29 |
2015-10-02 |
노렉스, 인크. |
스피로-락탐 nmda 수용체 조절인자 및 그의 용도
|
|
PE20151437A1
(es)
*
|
2013-01-29 |
2015-10-10 |
Naurex Inc |
Moduladores de receptores nmda de espiro-lactama y sus usos
|
|
LT3514158T
(lt)
*
|
2013-01-29 |
2023-02-10 |
Aptinyx Inc. |
Spirolaktaminiai nmda receptoriaus moduliatoriai ir jų panaudojimas
|
|
PH12015501596B1
(en)
|
2013-01-29 |
2023-12-06 |
Aptinyx Inc |
Spiro-lactam nmda receptor modulators and uses thereof
|
|
CN109415372B
(zh)
*
|
2016-05-19 |
2021-01-15 |
阿普廷伊克斯股份有限公司 |
螺-内酰胺nmda受体调节剂及其用途
|
|
WO2017201285A1
(en)
|
2016-05-19 |
2017-11-23 |
Aptinyx Inc. |
Spiro-lactam nmda receptor modulators and uses thereof
|